Advertisement
ADAP vs AKBA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADAP is a Buy and AKBA is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ADAP’s FA Score shows that 0 FA rating(s) are green whileAKBA’s FA Score has 0 green FA rating(s).
- ADAP’s FA Score: 0 green, 5 red.
- AKBA’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ADAP’s TA Score shows that 6 TA indicator(s) are bullish while AKBA’s TA Score has 4 bullish TA indicator(s).
- ADAP’s TA Score: 6 bullish, 4 bearish.
- AKBA’s TA Score: 4 bullish, 4 bearish.
Price Growth
ADAP (@Biotechnology) experienced а +9.10% price change this week, while AKBA (@Biotechnology) price change was +3.92% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +9.39%. For the same industry, the average monthly price growth was +14.41%, and the average quarterly price growth was +12.94%.
Reported Earning Dates
ADAP is expected to report earnings on Nov 05, 2025.
AKBA is expected to report earnings on Nov 06, 2025.
Industries' Descriptions
@Biotechnology (+9.39% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| ADAP | AKBA | ADAP / AKBA | |
| Capitalization | 67.1M | 974M | 7% |
| EBITDA | -50.18M | 6.59M | -762% |
| Gain YTD | -53.035 | 95.263 | -56% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 180M | 185M | 97% |
| Total Cash | 59.6M | 113M | 53% |
| Total Debt | 48.7M | 54.1M | 90% |
ADAP | AKBA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 52 | 76 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 52 Fair valued | 75 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 100 | |
PRICE GROWTH RATING 1..100 | 65 | 35 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ADAP's Valuation (52) in the Biotechnology industry is in the same range as AKBA (75). This means that ADAP’s stock grew similarly to AKBA’s over the last 12 months.
ADAP's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as AKBA (100). This means that ADAP’s stock grew similarly to AKBA’s over the last 12 months.
ADAP's SMR Rating (97) in the Biotechnology industry is in the same range as AKBA (100). This means that ADAP’s stock grew similarly to AKBA’s over the last 12 months.
AKBA's Price Growth Rating (35) in the Biotechnology industry is in the same range as ADAP (65). This means that AKBA’s stock grew similarly to ADAP’s over the last 12 months.
AKBA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ADAP (100). This means that AKBA’s stock grew similarly to ADAP’s over the last 12 months.
| ADAP | AKBA | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 84% | 1 day ago 89% |
| Stochastic ODDS (%) | 1 day ago 82% | 1 day ago 75% |
| Momentum ODDS (%) | 1 day ago 82% | 1 day ago 86% |
| MACD ODDS (%) | 1 day ago 82% | 1 day ago 88% |
| TrendWeek ODDS (%) | 1 day ago 80% | 1 day ago 84% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 85% |
| Advances ODDS (%) | 6 days ago 78% | 1 day ago 86% |
| Declines ODDS (%) | 8 days ago 90% | 8 days ago 85% |
| BollingerBands ODDS (%) | 1 day ago 84% | 6 days ago 90% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 87% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| BRZIX | 13.22 | 0.10 | +0.76% |
| BlackRock Sus Adg Intl Eq Ins | |||
| BGPFX | 13.76 | 0.10 | +0.74% |
| Baillie Gifford Developed EAFE All Cap 3 | |||
| RTSSX | 40.90 | 0.18 | +0.44% |
| Russell Inv Tax-Managed US Mid&Sm Cap S | |||
| AEYIX | 8.71 | N/A | N/A |
| American Century Equity Income C | |||
| WPVLX | 33.83 | N/A | N/A |
| Weitz Multi Cap Equity-Investor Cl | |||